Merck earnings top estimates amid solid demand for Keytruda cancer drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Leerink Partners Reiterates Outperform Rating on Merck (MRK)
November 1, 2024 7:20 AM EDTLeerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating on Merck (NYSE: MRK).
The analyst comments "Bottom Line: Gardasil remained the primary topic for Merck (MRK, OP) earnings and continues to weigh on the stock, which is trading at a 13.6 PE multiple, below most of its... More
